The authors declare that they have no competing interests.
YN directed this study. YN and MK collected samples. MK, SI, KM, SU, AT, and HK participated in the design of the study and performed the statistical analyses. All authors read and approved the final manuscript.
Denosumab is a fully human monoclonal antibody that inhibits receptor activator of nuclear factor kappa-β ligand (RANKL). Previous reports have shown that denosumab treatment of osteoporotic patients decreases bone resorption and fracture risk, but there have been no clinical studies on changes in bone turnover markers, 1,25(OH)2D3, or parathyroid hormone (PTH) in denosumab therapy with or without bisphosphonate (BP) pre-treatment in Japan.
Here, we report such findings in 22 patients (11 in the denosumab alone group and 11 in the BP pre-treated group) with osteoporosis following 4 months of treatment. Bone metabolism had been inhibited by prior BP administration in the BP pre-treated group.
The bone resorption markers serum tartrate-resistant acid phosphatase type 5b and urinary type I collagen cross-linked N-telopeptide were significantly decreased from baseline values for the entire study period in both groups. The bone formation marker bone alkaline phosphatase was significantly decreased at 4 months in the denosumab alone group only, and N-terminal propeptide of type 1 procollagen was significantly decreased at 2 and 4 months in the denosumab alone group versus no remarkable change in the BP pre-treated group. In the denosumab alone group, 1,25(OH)2D3 and PTH were significantly increased at 1 week and decreased gradually thereafter, but these did not change notably in the BP pre-treated group.
Our results suggest that treatment with denosumab causes a strong inhibitory effect on bone resorption markers and mild inhibitory effect on bone formation markers. 1,25(OH)2D3 and PTH were significantly increased by denosumab but these did not change in the BP pre-treated group.
Current Controlled Trials NCT02156960. Registered 31 May 2014.
Christiansen C. Skeletal osteoporosis. J Bone Miner Res. 1993;8 Suppl 2:S475–80. Review. PubMed
Rinotas V, Niti A, Dacquin R, Bonnet N, Stolina M, Han CY, Kostenuik P, Jurdic P, Ferrari S, Douni E. Novel genetic models of osteoporosis by overexpression of human RANKL in transgenic mice. J Bone Miner Res. 2013 Epub ahead of print.
Gallagher JC, Jindal P, Lynette MS. Vitamin D does not Increase Calcium Absorption in Young Women: A Randomized Clinical Trial. J Bone Miner Res. 2013 Epub ahead of print.
Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr. 2008;88:582S–6S. PubMed
Soen S. New diagnostic criteria and guidelines on osteoporosis. Diagnostic criteria for primary osteoporosis : Year 2012 revision. (Article in Japanese). Clin Calcium. 2014;24:323–9. PubMed
Okano T. [Clinical application of serum 25OHD]. Clin Calcium. 2013;23:377–84. Article in Japanese. PubMed
Civitelli R, Ziambaras K. Calcium and phosphate homeostasis: Concerted interplay of new regulators. J Endocrinol Invest. 2011;34(7 Suppl):3–7. PubMed
Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Taga M, Nakamura T, et al. A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research Group. Osteoporos Int. 1999;10:183–92. CrossRefPubMed
- Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: a short-term study
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II